Tatva Chintan Pharma Chem Limited · NSE:TATVA
Tatva Chintan Pharma Chem — Q3 FY26 Earnings Presentation
37 slides from Tatva Chintan Pharma Chem's earnings presentation, Jan 21, 2026
Slide 1: Exchange filing cover letter
Date: 21 January 2026 Ref. No.: TCPCL/SEC/2025-26/00072 To, The General Manager, The Manager, Corporate relationship department, Listing department, BSE Limited National Stock Exchange of India Limited Phiroze Jeejeebhoy Towers, Exchange Plaza, C-1, Block-G, Dalal Street, Fort, Bandra-Kurla Complex,
Slide 2: Investor Presentation Q3FY26
Investor Presentation Tatva Chintan Pharma Chem Limited (TCPCL) Q3FY26 21 January 2026
Slide 3: Contents
Contents 01 02 03 04 Q3 FY 26 TATVA CHINTAN at Glance Product Categories Leading Sustainable Financial Performance practices coupled with cutting edge technology 05 06 07 08 Expansive international Why TATVA CHINTAN Industry Outlook Our Business presence with Marquee clientele 2
Slide 4: Consolidated Financial Performance
Consolidated Financial Performance 3
Slide 5: Q3 FY26: Financial Result highlights
Q3 FY26: Financial Result highlights Q3FY26 HIGHLIGHTS Revenue from Operations 1 (In ₹ Mn) EBIDTA (Excl. Other Income) & PAT & PAT Margin 1 (In ₹ Mn, %) EPS (In ₹) EBIDTA Margin 1 (In ₹ Mn, %) 300 20.0% 7.00 18.0% 19.0% 18.0% 160 11.5 8.0% 250 6.00 16.0% 11.0% 200 14.0% 140 % 9.0% 5.00 6.49 120 12.0
Slide 6: Q3FY26: Consolidated Numbers
Q3FY26: Consolidated Numbers Particulars (₹ Mn) Q3FY26 Q3FY25 YoY (%) Q2FY25 QoQ (%) 9MFY26 9MFY25 YoY (%) Revenue from Operation 1,313 859 53% 1,235 6% 3,717 2,749 35% Total Income 1,331 859 55% 1,245 7% 3,756 2,761 36% EBITDA (Excl. Other Income) 255 71 261% 222 15% 650 256 154% EBITDA Margin 19%
Slide 7: Q3 & 9MFY26: Operational highlights
Q3 & 9MFY26: Operational highlights OPERATING REVENUE SPLIT (IN %) Others Others 1% PTC 1% PTC 21% 23% PASC PASC 36% 34% Q3FY26 PTC 9MFY26 PTC SDA SDA ESS ESS ESS ESS SDA 1% SDA 1% 41% PASC 41% PASC Others Others Tatva Chintan Pharma Chem Limited 6
Slide 8: Consolidated Financial Highlights
Consolidated Financial Highlights REVENUE FROM OPERATIONS1 (IN ₹ MN) PROFITABILITY1 (IN ₹ MN) 90 57 EBITDA (Excluding Other Income) & EBITDA Margin PAT & PAT Margin 11% 8% 1% 9% 4,336 75 25% 14% 17% 9% 17% 22% 4,236 23 39 3,935 3,827 650 1,082 3,717 342 959 317 455 682 57 606 304 FY22 FY23 FY24 FY25
Slide 9: Consolidated Statement of Profit & Loss
Consolidated Statement of Profit & Loss Particulars (₹ Mn) 31-Mar- 20 31-Mar- 21 31-Mar- 22 31-Mar- 23 31-Mar- 24 31-Mar- 25 30-Sep-25 31-Dec-25 Audited Audited Audited Audited Audited Audited Unaudited U naudited Income Revenue from operations 2,632.39 3,003.59 4,336.47 4,236.12 3,935.04 3,827.14 2
Slide 10: Consolidated Statement of Balance Sheet
Consolidated Statement of Balance Sheet Particulars (₹ Mn) 31-Mar-20 31-Mar-21 3 1-Mar-22 31-Mar-2 3 31-Mar-24 31-Mar-25 3 0-Sep-25 Audited Audited Audited Audited Audited Audited U naudited Assets Fixed Assets 1,110.60 1,203.51 1,592.96 1,957.71 4,265.35 5,255.52 5,022.90 Capital work-in-progress 4
Slide 11: TATVA CHINTAN at Glance
“a TATVA 4, CHINTAN N | at Glance _ @ S.
Slide 12: TATVA CHINTAN at Glance
TATVA CHINTAN at Glance INTEGRATED SPECIALTY CHEMICAL COMPANY, PRESENT ACROSS THE VALUE CHAIN • Established by first generation entrepreneur engineers in Manufacturing Products Revenue Split – FY25 1996 • Plants located at Ankleshwar and Dahej SEZ, Gujarat with an existing combined installed reactor
Slide 13: Product Categories
Product Categories 12
Slide 14: Phase Transfer Catalyst (PTC) – a Catalyst with Innumerable Benefits
Phase Transfer Catalyst (PTC) – a Catalyst with Innumerable Benefits WHAT ARE PTC? BENEFITS DEMAND DRIVERS • PTC are used to facilitate the • Offers faster reactions • Rising demand for technologically TATVA CHINTAN’S migration of a reactant from one • Higher conversion/yields, advanced environment-
Slide 15: Structure Directing Agents (SDA)
Structure Directing Agents (SDA) – an important ingredient for making the world more sustainable WHAT ARE SDA? BENEFITS DEMAND DRIVERS • High purity Quaternary salts that SDAs are important raw material for • With the recent developments in TATVA CHINTAN’S helps in the formation of creation of high
Slide 16: Electrolysis – a better and greener way of producing SDAs
Electrolysis – a better and greener way of producing SDAs ABOUT ELECTROLYSIS BENEFITS • TATVA started R&D into developing SDA • Electrolysis is considered as a ‘green’ since 2007 chemistry process wherein apart from a single starting raw material, the process largely uses • In 2015, it received comm
Slide 17: Electrolyte Salts & Solutions (ESS)
Electrolyte Salts & Solutions (ESS)– aiding the technological thrust WHAT ARE ELECTROLYTE BENEFITS DEMAND DRIVERS TATVA CHINTAN’S SALTS? • Due to their properties like fast Currently, these are used along with charging ability, superior low temperature performance, long Lithium battery in EV vehicle
Slide 18: Pharmaceuticals and Agrochemicals Intermediates and other Specialty Chemicals (PASC)
Pharmaceuticals and Agrochemicals Intermediates and other Specialty Chemicals (PASC) – WHICH PRODUCTS ARE END USER INDUSTRY TATVA CHINTAN’S TATVA is the largest MANUFACTURED? APPLICATION POSITION IN PASC producer of Glymes in India and third • Various pharmaceutical and agrochemical products such as
Slide 19: Continuous Flow Chemistry
Continuous Flow Chemistry – sophisticated method with analytical expertise ABOUT BENEFITS PROCESS • TATVA CHINTAN started R&D into • Continuous Flow Chemistry is • Structure directing agents are continuous flow chemistry since considered as a ‘green’ chemistry converted to Zeolite based catalysts 20
Slide 20: Value derived from Product Categories
Value derived from Product Categories REVENUE FROM EACH PRODUCT CATEGORY1 (In ₹ Mn.) 2,248 Considering the wide range of applications of our products, Tatva Chintan can cater to 1,655 customers across wide spectrum of 1,520 Chemical Industries which ensures a 1,432 1,335 sustainable business model.
Slide 21: Leading Sustainable practices coupled with cutting edge technology
Leading Sustainable practices coupled with cutting edge technology 20
Slide 22: Integrated and Modern Manufacturing Facility
Integrated and Modern Manufacturing Facility ANKLESHWAR DAHEJ SEZ • Both the plants are in-close proximity to • Manufacturing facility started in 1996 • Manufacturing started in 2017 Hazira port. • Converted into a ‘zero liquid effluent discharge’ facility from • Company has having sophisticated qua
Slide 23: One of the prominent Research & Development center
One of the prominent Research & Development center R&D CAPITAL AND REVENUE EXPENDITURE • Dedicated R&D facility at Vadodara recognized by the Department of (In ₹ Mn.) 300.00 Scientific and Industrial Research (“DSIR”), Government of India. • Equipped with glass assemblies, continuous flow reactors,
Slide 24: …With a focus on 'green' chemistry processes
…With a focus on ‘green’ chemistry processes Tatva Chintan’s ‘green’ chemistry is based on the principles of clean chemistry, minimum requirement of auxiliary substances, minimum waste and by-products and safe chemistry • Undertaking various ‘green’ chemistry processes • By deploying electrolysis fo
Slide 25: Expansive international presence with Marquee clientele
Expansive international presence with Marquee clientele 24
Slide 26: Fostered long term relationship with marquee clientele
Fostered long term relationship with marquee clientele while continuously expanding presence in global market ESTEEMED CUSTOMERS EXPORTS • Tatva exports products to over 25+ countries viz. USA, China, Germany, Japan, South Africa and UK. • Subsidiaries facilitates overseas operations:- • Tatva Chint
Slide 27: Why TATVA CHINTAN
7 Why TATVA uit % CHINTAN YY _®
Slide 28: Investment Rationale
Investment Rationale Presence in niche Track record of Wide basket of Continuous focus High industry Capex to boost the specialty chemicals developing wide products are used in on R&D and in house barriers as new capacities and pave space with limited product basket varied industries developed entra
Slide 29: Industry Outlook
Industry Outlook 28
Slide 30: India's rapidly expanding footprint in Global Chemical Market
India's rapidly expanding footprint in Global Chemical Market SHARE OF COUNTRIES IN GLOBAL TRENDS IN SPECIALTY CHEMICALS LANDSCAPE CHEMICAL INDUSTRY (IN %) Indian Chemical Move towards Opportunity Industry got sustainable product for Indian Advantage vs development: Manufacturers: CHINA 39% China du
Slide 31: Global Chemical Industry market size
Global Chemical Industry GLOBAL PTC SDA CHEMICAL Commodity Chemicals INDUSTRY • Basic Chemicals 1,190 1.19 MARKET SIZE • Manufactured In large volumes Mkt Size 2022 (USD Mn) Mkt Size 2022 (USD bn) • Mkt Size USD 3,700bn • ~Expected 4% CAGR 1,640 5.5% 1.65 5.6% 5,030 Speciality Chemicals Mkt Size 202
Slide 32: Our Business
Our Business 31
Slide 33: Major Events & Milestones
Major Events & Milestones 1996 2007 2013 2017 2019 2021 Incorporation of our Expansion of Achieved turnover Set up our Dahej SEZ Incorporation of • Listed on Company manufacturing capacity at of ₹ 500.00 million Manufacturing Facility Tatva Chintan Europe BSE and NSE our Ankleshwar BV, a wholly owne
Slide 34: Leadership and Management
Leadership and Management Chintan Nitinkumar Ajaykumar Shekhar Rasiklal Dr. Manher Chimanlal CA Subhash Dr. Avani Rajesh Shah Mansukhlal Patel Somani Desai Ambubhai Patel Umatt M A NA G I N G D I RE C T O R WHOLE TIME DIRECTOR WHOLE TIME DIRECTOR I N D E P E ND E N T D I RE C T O R I N D E P E ND E
Slide 35: Shareholder Information
Shareholder Information SHAREHOLDING PATTERN- December 2025 (IN %) NSE Ticker TATVA BSE Ticker 543321 IPO Listing Date 29 July 2021 Share Price (₹)^ 1,334.20 PROMOTER 72.02% Market Cap (₹ Mn)^ 31,210 MF 3.25% % Free Float^ 27.98% Dec PUBLIC 19.66% Free float market cap (₹ Mn)^ 8,733 2025 FPI 4.17% S
Slide 36: Safe Harbor
Safe Harbor Certain statements in this presentation concerning our future growth prospects are forward looking statements, which involve a number of risks, and uncertainties that could cause actual results to differ materially from those in such forward-looking statements. The company's results may
Slide 37: Thank You
January 2026 Thank You TATVA CHINTAN PHARMA CHEM LIMITED INVESTOR RELATIONS AT CORPORATE OFFICE TATVA CHINTAN Plot No. 353, G.I.D.C, Mr. Ajesh Pillai Makarpura, Vadodara – 390 010, Gujarat, India ajesh@tatvachintan.com BSE: 543321 NSE: TATVA CIN: L24232GJ1996PLC029894 www.tatvachintan.com Copyright
Tatva Chintan Pharma Chem — Q3 FY26 Earnings Presentation on 6ix